Evotec’s CNS deal with Bristol Myers gets $50M infusion and eight-year extension

Bristol Myers Squibb is upping the ante on its neurodegeneration partnership with German biotech Evotec. The Big Pharma will dole out $50 million upfront to expand the seven-year collaboration by another eight years.

Originally inked with Celgene, the partnership will now balloon to a potential $4…